Article source：Kexing Biopharm
Aug 26,2025
View：
38 Kexing Biopharm, a pioneer in China’s biopharmaceutical company, has officially launched its KX-BODY antibody technology platform. As a core component of the company’s “3KX” innovation strategy, KX-BODY represents a milestone in the evolution of antibody drug research and development. The platform is designed to accelerate the creation of monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), and multispecific antibodies, while integrating diverse therapeutic modalities into one versatile antibody-based framework.
This breakthrough demonstrates Kexing’s commitment to scientific innovation and global competitiveness in the biopharma sector, opening a new chapter in the company’s platform-driven innovation model.
The KX-BODY platform has been developed to support next-generation biologics with advanced modularity, precision, and scalability. It is structured into three interconnected sub-platforms, each addressing specific needs in antibody discovery and engineering:
FIT-BODY is Kexing’s monoclonal antibody discovery platform. It enables multi-pathway, high-throughput screening combined with epitope-precise localization, ensuring that antibody candidates are optimized for specificity, efficacy, and safety. This sub-platform accelerates the development cycle of novel mAbs while maintaining world-class quality standards.
Key Features of FIT-BODY:
Advanced monoclonal antibody discovery engine.
Epitope-focused precision screening.
High throughput for rapid candidate generation.
Powered by Kexing’s proprietary DS/ES technology, FIGHT-BODY provides a robust framework for creating bispecific antibodies that maintain the natural IgG structure. This innovation ensures high stability, manufacturability, and therapeutic efficacy, addressing key challenges often associated with bsAb development.
Key Features of FIGHT-BODY:
Proprietary DS/ES technology for antibody pairing.
Natural IgG-like format for enhanced stability.
Broad application potential in oncology, immunology, and infectious diseases.
FLEX-BODY is a customizable modular platform that allows for the assembly of multi-functional antibodies and fusion proteins. By integrating multiple functional domains, FLEX-BODY can create tailor-made therapeutic molecules targeting complex diseases.
Key Features of FLEX-BODY:
Modular antibody-fusion constructs.
Capability to integrate multiple therapeutic modalities.
Designed for flexibility across disease areas.
The launch of KX-BODY injects new vitality into Kexing Biopharm’s innovation ecosystem. The platform strengthens the company’s ability to:
Accelerate Drug Discovery: High-throughput antibody identification shortens R&D timelines.
Enhance Innovation Value: Proprietary DS/ES technology elevates the company’s intellectual property portfolio.
Expand Treatment Options: From oncology to autoimmune and infectious diseases, KX-BODY offers versatile applications.
Integrate Therapeutic Modalities: Antibodies serve as the backbone for multi-format drug development.
KX-BODY thus represents a pivotal step in building Kexing’s global innovation brand and scientific competitiveness.
The KX-BODY platform is one of the three pillars of Kexing’s broader “3KX” strategy, alongside KX-FUSION and KX-Exosome. While KX-FUSION focuses on fusion protein therapeutics and KX-Exosome explores exosome-based innovations, KX-BODY serves as the antibody-centric pillar. Together, these platforms provide a diversified innovation engine that drives Kexing’s long-term growth and international expansion.
By unveiling the KX-BODY platform, Kexing Biopharm is positioning itself as a strong partner for international collaborations in antibody therapeutics. The modularity and scalability of FIT-BODY, FIGHT-BODY, and FLEX-BODY create unique opportunities for co-development, licensing, and clinical advancement with global pharmaceutical companies and research institutions.
This global perspective aligns with Kexing’s strategy of combining domestic market leadership with international regulatory compliance, paving the way for its next-generation antibody drugs to enter regulated markets such as the United States, Europe, and beyond.
The KX-BODY antibody technology platform marks a new era for Kexing Biopharm. With FIT-BODY, FIGHT-BODY, and FLEX-BODY at its core, the platform integrates precision, innovation, and flexibility to advance antibody-based therapeutics. As part of the company’s 3KX innovation strategy, KX-BODY not only strengthens Kexing’s scientific foundation but also sets the stage for global partnerships and market expansion.
Through this milestone, Kexing Biopharm demonstrates its unwavering commitment to delivering innovative, patient-centered therapies while building a stronger international presence in the competitive world of biopharmaceuticals.
BACK TO LIST
Oct 29,2024
